DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Long GV, Flaherty KT, Stroyakovskiy D. et al.
Dabrafenib plus trametinib vs. dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Ann Oncol 2017;
28: 1631-1639
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.